close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

246.20 +2.40 (+0.98%)
Official Closing Price Updated: 7:00 PM EDT, Aug 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
99 100 Next >
News headline image
2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off ↗
Via The Motley Fool
News headline image
3 Fantastic Stocks That Could Enjoy a Santa Claus Rally ↗
Via The Motley Fool
News headline image
2 Top Dividend Stocks to Buy and Hold Through 2025 and Beyond ↗
Via The Motley Fool
News headline image
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields ↗
 
Via Benzinga
News headline image
AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth. Will AbbVie Stock Come Back? ↗
AbbVie has a lofty goal in cancer treatment, and it could come to fruition in 2025. 
Via Investor's Business Daily
News headline image
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever ↗
These companies have ingrained competitive advantages in an evergreen industry backed by decades of dividend growth. 
Via The Motley Fool
News headline image
Analyst Scoreboard: 19 Ratings For AbbVie ↗
 
Via Benzinga
News headline image
Check Out What Whales Are Doing With ABBV ↗
 
Via Benzinga
News headline image
Check Out What Whales Are Doing With ABBV ↗
 
Via Benzinga
News headline image
Neurocrine Wins FDA Approval For Genetic Disorder Drug ↗
The company can launch within a week, says Chief Executive Kyle Gano. 
Via Investor's Business Daily
News headline image
1 Magnificent S&P 500 Dividend Stock Down 14% to Buy and Hold Forever ↗
Via The Motley Fool
Topics Stocks
News headline image
AbbVie's Early Parkinson's Candidate Hits Primary Goal In Pivotal Late-Stage Study ↗
AbbVie reports Phase 3 TEMPO-2 trial success for tavapadon, a once-daily Parkinson's treatment, showing significant symptom improvement and safety. 
Via Benzinga
News headline image
Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts ↗
Alector's AL002 misses primary endpoint in Alzheimer's trial. BofA downgrades stock, cuts price target, and highlights near-term challenges. 
Via Benzinga
News headline image
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields ↗
 
Via Benzinga
News headline image
3 High-Yield Dividend Growth Stocks to Buy in December and Hold for a Decade or Longer ↗
Via The Motley Fool
News headline image
Spotlight on AbbVie: Analyzing the Surge in Options Activity ↗
 
Via Benzinga
News headline image
(ABBV) - Analyzing AbbVie's Short Interest ↗
 
Via Benzinga
News headline image
Market Whales and Their Recent Bets on ABBV Options ↗
 
Via Benzinga
News headline image
It’s Been A Tough Month For Healthcare Stocks ↗
It’s been a very difficult month for the healthcare sector not only because of disappointing company news but also disruption caused by the election and future policy issues. 
Via Talk Markets
Topics ETFs Stocks / Equities
News headline image
3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later ↗
Via The Motley Fool
News headline image
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever ↗
Via The Motley Fool
News headline image
Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce ↗
Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is cut by 17%. 
Via Benzinga
News headline image
2 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income ↗
Via The Motley Fool
News headline image
The Stock Market Is Soaring but These 2 Stocks Are Still Dirt Cheap Buys ↗
Via The Motley Fool
News headline image
Unpacking the Latest Options Trading Trends in AbbVie ↗
 
Via Benzinga
News headline image
Where Will AbbVie Be in 5 Years? ↗
Via The Motley Fool
News headline image
3 Dividend Stocks That Are Screaming Buys in November ↗
Political uncertainty has created buying opportunities among blue-chip healthcare stocks with big-time dividends. 
Via The Motley Fool
News headline image
AbbVie Jumps Nearly 4% On An Upgrade Despite Bristol Myers-Tied Setback ↗
AbbVie's schizophrenia treatment, courtesy of its Cerevel takeover, missed the market in two studies. But an analyst says there's still more to like. 
Via Investor's Business Daily
News headline image
This Elastic Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday ↗
 
Via Benzinga
News headline image
What To Do After The Worst Week For Healthcare Stocks Since March 2020? ↗
The market was quiet today but we should still expect some gains through year -end albeit a bit choppy. 
Via Talk Markets
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.